Effect of imipramine on 1-methyl-4-phenylpyridinium ion-induced hydroxyl radical generation in rat striatum

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1588, Issue 2, 2002, Pages 173-178

  Obata, Toshio ^a   Egashira, Toru ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

1 Methyl 4 phenylpyridinium ion (MPP+); Dopamine; Hydroxyl radical; Imipramine; Parkinson's disease

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 2,3 DIHYDROXYBENZOIC ACID; DOPAMINE; HYDROXYL RADICAL; IMIPRAMINE; IRON; RESERPINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DIALYSATE; DOPAMINE RELEASE; DRUG EFFECT; EXTRACELLULAR FLUID; FEMALE; LINEAR SYSTEM; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CORPUS STRIATUM; DOPAMINE; FEMALE; HYDROXYBENZOIC ACIDS; HYDROXYL RADICAL; IMIPRAMINE; LACTAMS; MICRODIALYSIS; MONOAMINE OXIDASE; PYRIDONES; RATS; RATS, WISTAR;

ANIMALIA;

EID: 0037145698     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0925-4439(02)00162-X     Document Type: Article

References (33)

1. Prakash C., Cui D. Metabolism and excretion of a new antianxiety drug candidate, CP-93, 393, in cynomolgus monkeys: identification of the novel pyrimidine ring cleaved metabolites. Drug Metab. Dispos. 25:1997;1395-1406.
2. Edwards D.J., Burns M.O. Effects of tricyclic antidepressants upon human platelet monoamine oxidase. Life Sci. 15:1974;2045-2058.
3. Obata T., Inada T., Yamanaka Y. Intracranial microdialysis of salicylic acid to detect hydroxyl radical generation by antidepressant drugs in the rat. Neurosci. Res. Commun. 21:1997;223-229.
4. Roth J.A., Gillis C.N. Deamination of beta-phenylethylamine by monoamine oxidase-inhibition by imipramine. Biochem. Pharmacol. 23:1974;2537-2545.
5. Neff N.H., Yang H.-Y.T. Another look at the monoamine oxidases and the monoamine oxidase inhibitor drugs. Life Sci. 14:1974;2061-2074.
6. Youdim M.B.H., Finberg J.P. New directions in monoamine oxidase A and B selective inhibitors and substrates. Biochem. Pharmacol. 41:1991;155-1562.
7. Chiba K., Trevor A., Castagnoli N. Jr. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun. 120:1984;574-578.
8. Markey S.P., Johannessen J.N., Chiueh C.C., Burns R.S., Herkenham M.A. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature. 311:1984;464-467.
9. Fowler C.J., Beneditti M.S. The metabolism of dopamine by both forms of monoamine oxidase in the brain and its inhibition by cimoxatone. J. Neurochem. 40:1983;1534-1541.
10. Chiueh C.C., Wu R.-M., Mohanakumar K.P., Sternberger L.M., Krishna G., Obata T., Murphy D.L. In vivo generation of hydroxyl radicals and MPTP-induced dopaminergic toxicity in the basal ganglia. Ann. N. Y. Acad. Sci. 738:1994;25-36.
11. Gerlach M., Ben-Shachar D., Riederer P., Youdim M.B.H. Altered brain metabolism of iron as a cause of neurodegenerative diseases? J. Neurochem. 63:1994;793-807.
12. Riederer P., Sofic E., Rausch W.-D., Schmidt B., Reynolds G.P., Jellinger K., Youdim M.B.H. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52:1989;515-520.
13. +. Free Radic. Biol. Med. 13:1992;581-583.
14. Kinemuchi H., Fowler C.J., Tipton K.F. The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its relevance to Parkinson disease. Neurochem. Int. 11:1987;359-373.
15. Fornstedt B., Pileblad E., Carlsson A. In vivo autoxidation of dopamine in guinea pig striatum increases with age. J. Neurochem. 55:1990;655-659.
16. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
17. Paxinos G., Watson C. The Rat Brain Stereotaxic Coordinates. 2nd ed. 1982;Academic Press, Sydney.
18. Floyd R.A., Watson J.J., Wong P.K. Sensitive assay of hydroxyl free radical formation utilizing high pressure liquid chromatography with electrochemical detection of phenol and salicylate hydroxylation products. J. Biochem. Biophys. Methods. 10:1984;221-235.
19. Halliwell B., Kaur H., Ingleman-Sundberg M. Hydroxylation of salicylate as an assay for hydroxyl radicals: a cautionary note. Free Radic. Biol. Med. 10:1991;439-441.
20. +) on dopamine and serotonin metabolism in rat striatum as assayed in vivo by a micro-dialysis technique. J. Neural Transm. 70:1987;241-250.
21. Kato T., Dong B., Ishii K., Kinemuchi H. Brain dialysis: in vivo metabolism of dopamine and serotonin by monoamine oxidase A but not B in the striatum of unrestrained rats. J. Neurochem. 46:1986;1277-1282.
22. Di Monte D.A., Royland J.E., Anderson A., Castagnoli K., Castagnoli N. Jr., Langston J.W. Inhibition of monoamine oxidase contributes to the protective effect of 7-nitroindazole against MPTP neurotoxicity. J. Neurochem. 69:1997;1771-1773.
23. Mytilineou C., Leonardi E.K., Radcliffe P., Heinonen E.H., Han S.K., Werner P., Cohen G., Olanow C.W. Deprenyl and desmethylselegiline protect mesencephalic neurons from toxicity induced by glutathione depletion. J. Pharmacol. Exp. Ther. 284:1998;700-706.
24. Kinemuchi H., Arai Y., Toyoshima Y. Participation of brain monoamine oxidase B form in the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: relationship between the enzyme inhibition and the neurotoxicity. Neurosci. Lett. 58:1985;195-200.
25. Fowler C.J., Oreland L., Marcusson J., Winblad B. Titration of human brain monoamine oxidase-A and -B by clorgyline and L-deprenyl. Naunyn-Schmiedeberg's Arch. Pharmacol. 311:1980;263-272.
26. Fowler C.J., Ross S.B. Selective inhibitors of monoamine oxidase A and B: biochemical, pharmacological, and clinical properties. Med. Res. Rev. 4:1984;323-358.
27. Coppen A. Indoleamines and affective disorders. J. Psychiatr. Res. 9:1972;163-171.
28. Prange A.J. Jr., Wilson I.C., Lynn C.W., Alltop L.B., Stikeleather R.A. L-Tryptophan in mania. Contribution to a permissive hypothesis of affective disorders. Arch. Gen. Psychiatry. 30:1974;56-62.
29. + in rat striatum. Brain Res. 828:1999;68-73.
30. Dedon P.C., Plastaras J.P., Rouzer C.A., Marnett L.J. Indirect mutagenesis by oxidative DNA damage: formation of the pyrimidopurinone adduct of deoxyguanosine by base propenal. Proc. Natl. Acad. Sci. U. S. A. 95:1998;11113-11116.
31. Perry T.L., Yong V.W. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci. Lett. 67:1986;269-274.
32. Pilas B., Sarna T., Kalyanaraman B., Swartz H.M. The effect of melanin on iron associated decomposition of hydrogen peroxide. Free Radic. Biol. Med. 4:1988;285-293.
33. Ben-Shachar D., Riederer P., Youdim M.B.H. Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J. Neurochem. 57:1991;1609-1614.